21:08 , May 23, 2019 |  BC Innovations  |  Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
18:54 , Mar 21, 2019 |  BC Extra  |  Financial News

Imago to deploy $40M series B for Phase II trials

Imago raised $40 million Thursday in a tranched series B round led by new investor Omega Funds to support completing Phase II trials of its lead compound, IMG-7289, for hematological indications. An Imago BioSciences Inc....
05:01 , Feb 5, 2019 |  BC Extra  |  Financial News

Real-world analytics company Aetion tops off series B

Aetion Inc. (New York, N.Y.) raised an additional $27 million in its series B round Tuesday to continue building its real-world evidence analytics platform. New investors Sanofi (Euronext:SAN; NASDAQ:SNY), UCB S.A. (Euronext:UCB), McKesson Ventures and...
18:29 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Neurodegeneration play Rheostat raises $23M series A

Rheostat Therapeutics (Cambridge, Mass.) raised $23 million in a series A round to bring its first programs in neurodegenerative disease to IND. The round was co-led by MRL Ventures Fund and AbbVie Ventures, with participation...
00:06 , Nov 27, 2018 |  BC Extra  |  Financial News

Neurodegeneration play Rheostat raises $23M series A

Rheostat Therapeutics (Cambridge, Mass.) raised $23 million in a series A round to bring its first programs in neurodegenerative disease to IND. The round was co-led by MRL Ventures Fund and AbbVie Ventures, with participation...
15:56 , Nov 16, 2018 |  BC Week In Review  |  Financial News

M Ventures leads $30M series A for RNA start-up Ribometrix

RNA company Ribometrix Inc. (Durham, N.C.) raised $30 million in a series A round led by M Ventures on Nov. 13. Fellow new investors Amgen Ventures, Pappas Capital and Illumina Ventures also participated, as did...
15:54 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round on Nov. 13 to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to...
16:25 , Nov 13, 2018 |  BioCentury  |  Finance

Kymera’s degradation toolbox

As the protein degradation space continues to gain traction, Kymera Therapeutics LLC has attracted interest from investors to the tune of $65 million to bring its first program to the clinic. 6 Dimensions Capital, Bessemer...
12:03 , Nov 13, 2018 |  BC Extra  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to both an E3...
11:35 , Nov 13, 2018 |  BC Extra  |  Financial News

M Ventures leads $30M series A for RNA start-up Ribometrix

RNA company Ribometrix Inc. (Durham, N.C.) raised $30 million in a series A round led by M Ventures. Fellow new investors Amgen Ventures, Pappas Capital and Illumina Ventures also participated, as did existing investors SV...